CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Serological testingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2944 patients receiving nasal high flow Wiki 1.00

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D011024 Pneumonia, Viral NIH 0.13
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak

A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to the rest of the world, including Europe and explicitly affects the respiratory system, generating Coronavirus disease 2019 (COVID-19). This study is a monocentric interventional prospective cohort study. After signing a written informed consent, participants will be recruited for questionnaire completion and blood sampling. Sample storage and analysis will be performed at the laboratory of microbiology of the UZ Brussel. - To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5. - To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.

NCT04426292 Sars-CoV2 Diagnostic Test: Serological testing

Primary Outcomes

Description: - To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5.

Measure: Seroprevalence

Time: Change from baseline to 2 months and 5 months timepoint

Description: - To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.

Measure: seroconversions

Time: Change from baseline to 2 months and 5 months timepoint

Secondary Outcomes

Description: - To document the incidence of new definite cases of COVID-19 (based on self-reported positive PCR testing on nasopharyngeal swab) among employees of the UZ Brussel over a period of five months.

Measure: Incidence of definite cases

Time: Change from baseline to 2 months and 5 months timepoint

Description: - To document the incidence of new probable cases of COVID-19 (based on study questionnaire) among employees of the UZ Brussel over a period of five months.

Measure: Incidence of probable cases

Time: Change from baseline to 2 months and 5 months timepoint

Description: - To document the SARS-CoV-2 antibody kinetics after confirmed and probable COVID-19. Specifically (1) electrostatic interactions, (2) dispersion forces, (3) hydrogen bonds, and (4) hydrophobic interactions.

Measure: Antibody kinetics

Time: Change from baseline to 2 months and 5 months timepoint

Description: - To investigate potential work-related risk factors for SARS-CoV-2 infection among employees of the UZ Brussel.

Measure: Potential work-related risk factors

Time: Change from baseline to 2 months and 5 months timepoint

Description: - To quantify the proportion of asymptomatic seroconversions among employees of the UZ Brussel over a period of five months.

Measure: Proportion of asymptomatic seroconversions

Time: Change from baseline to 2 months and 5 months timepoint

Description: - To document the concerns of HCW and non-HCW about their safety for infection with COVID-19.

Measure: Concerns for safety for infection with COVID-19

Time: Change from baseline to 2 months and 5 months timepoint

No related HPO nodes (Using clinical trials)